{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:03:51Z","timestamp":1793156631958,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Cole Foundation"},{"name":"Foundation of Charles-Bruneau"},{"name":"Network of Applied Genetic Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24355-3","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T13:49:57Z","timestamp":1763473797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of xanthine oxidase and inosine monophosphate dehydrogenase polymorphisms on 6-mercaptopurine treatment response in pediatric acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Zarina","family":"Sabirova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moncef Taki Eddine","family":"Boucetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania Razane","family":"Bensouyad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Gagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Th\u00e9or\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Laverdi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sinnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thai-Hoa","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Krajinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"1","key":"24355_CR1","first-page":"32","volume":"4","author":"F Azimi","year":"2014","unstructured":"Azimi, F., Jafariyan, M., Khatami, S., Mortazavi, Y. & Azad, M. Assessment of thiopurine-based drugs according to thiopurine S-methyltransferase genotype in patients with acute lymphoblastic leukemia. Iran J. Ped. Hematol. Oncol. 4(1), 32\u201338 (2014).","journal-title":"Iran J. Ped. Hematol. Oncol."},{"issue":"4","key":"24355_CR2","doi-asserted-by":"publisher","first-page":"151.22","DOI":"10.3390\/toxics10040151","volume":"10","author":"Oliwia","year":"2022","unstructured":"Oliwia, et al. Cytotoxicity of thiopurine drugs in patients with inflammatory bowel disease. Toxics 10(4), 151.22. https:\/\/doi.org\/10.3390\/toxics10040151 (2022).","journal-title":"Toxics"},{"issue":"4","key":"24355_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.101095","volume":"32","author":"CG Mullighan","year":"2019","unstructured":"Mullighan, C. G. How advanced are we in targeting novel subtypes of ALL?. Best Pract. Res. Clin. Haematol. 32(4), 101095. https:\/\/doi.org\/10.1016\/j.beha.2019.101095 (2019).","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"9617","key":"24355_CR4","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui, C. H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. Lancet 371(9617), 1030\u20131043. https:\/\/doi.org\/10.1016\/S0140-6736(08)60457-2 (2008).","journal-title":"Lancet"},{"issue":"3","key":"24355_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaoncol.2015.0245","volume":"1","author":"S Bhatia","year":"2015","unstructured":"Bhatia, S. et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a children\u2019s oncology group study. JAMA Oncol. 1(3), 287\u2013295. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0245 (2015).","journal-title":"JAMA Oncol."},{"key":"24355_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2147\/IJN.S290466","volume":"16","author":"Y Zou","year":"2021","unstructured":"Zou, Y. et al. Preparation, characterization, pharmacokinetic, and therapeutic potential of novel 6-mercaptopurine-loaded oral nanomedicines for acute lymphoblastic leukemia. Int. J. Nanomedicine. 16, 1127\u20131141. https:\/\/doi.org\/10.2147\/IJN.S290466 (2021).","journal-title":"Int. J. Nanomedicine."},{"issue":"5","key":"24355_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1517\/17425255.2014.893294","volume":"10","author":"S Dulucq","year":"2014","unstructured":"Dulucq, S., Laverdi\u00e8re, C., Sinnett, D. & Krajinovic, M. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies. Expert Opin. Drug Metab. Toxicol. 10(5), 699\u2013719. https:\/\/doi.org\/10.1517\/17425255.2014.893294 (2014).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"6","key":"24355_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/MOP.0b013e32833fde85","volume":"22","author":"SW Paugh","year":"2010","unstructured":"Paugh, S. W., Stocco, G. & Evans, W. E. Pharmacogenomics in pediatric leukemia. Curr. Opin. Pediatr. 22(6), 703\u2013710. https:\/\/doi.org\/10.1097\/MOP.0b013e32833fde85 (2010).","journal-title":"Curr. Opin. Pediatr."},{"issue":"6","key":"24355_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3390\/genes11060679","volume":"11","author":"E Cecchin","year":"2020","unstructured":"Cecchin, E. & Stocco, G. Pharmacogenomics and personalized medicine. Genes 11(6), 679. https:\/\/doi.org\/10.3390\/genes11060679 (2020).","journal-title":"Genes"},{"issue":"10197","key":"24355_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","volume":"394","author":"DM Roden","year":"2019","unstructured":"Roden, D. M. et al. Pharmacogenomics. Lancet (London, England). 394(10197), 521\u2013532. https:\/\/doi.org\/10.1016\/S0140-6736(19)31276-0 (2019).","journal-title":"Lancet (London, England)."},{"issue":"37","key":"24355_CR11","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.3748\/wjg.v17.i37.4166","volume":"17","author":"K Bradford","year":"2011","unstructured":"Bradford, K. & Shih, D. Q. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J. Gastroenterol. 17(37), 4166\u20134173. https:\/\/doi.org\/10.3748\/wjg.v17.i37.4166 (2011).","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"24355_CR12","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling, M. V. et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update. Clin. Pharmacol. Ther. 105(5), 1095\u20131105. https:\/\/doi.org\/10.1002\/cpt.1304 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"24355_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","volume":"33","author":"JJ Yang","year":"2015","unstructured":"Yang, J. J. et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J. Clin. Oncol. 33(11), 1235\u20131242. https:\/\/doi.org\/10.1200\/JCO.2014.59.4671 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"24355_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s43440-021-00287-3","volume":"74","author":"T Texis","year":"2022","unstructured":"Texis, T. et al. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in natives and mestizos from Mexico. Pharmacol. Rep. 74(1), 257\u2013262. https:\/\/doi.org\/10.1007\/s43440-021-00287-3 (2022).","journal-title":"Pharmacol. Rep."},{"issue":"10","key":"24355_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1182\/blood-2017-05-782383","volume":"130","author":"T Moriyama","year":"2017","unstructured":"Moriyama, T. et al. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood 130(10), 1209\u20131212. https:\/\/doi.org\/10.1182\/blood-2017-05-782383 (2017).","journal-title":"Blood"},{"issue":"10","key":"24355_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jmoldx.2022.06.007","volume":"24","author":"VM Pratt","year":"2022","unstructured":"Pratt, V. M. et al. TPMT and NUDT15 genotyping recommendations: a joint consensus recommendation of the association for molecular pathology, clinical pharmacogenetics implementation consortium, college of american pathologists, dutch pharmacogenetics working group of the royal dutch pharmacists association, european society for pharmacogenomics and personalized therapy, and pharmacogenomics knowledgebase. J. Mol. Diagn. 24(10), 1051\u20131063. https:\/\/doi.org\/10.1016\/j.jmoldx.2022.06.007 (2022).","journal-title":"J. Mol. Diagn."},{"key":"24355_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/PGPM.S108123","volume":"10","author":"R Abaji","year":"2017","unstructured":"Abaji, R. & Krajinovic, M. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response. Pharmgenomics Pers. Med. 10, 143\u2013156. https:\/\/doi.org\/10.2147\/PGPM.S108123 (2017).","journal-title":"Pharmgenomics Pers. Med."},{"issue":"8","key":"24355_CR18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00228-008-0478-6","volume":"64","author":"S Sahasranaman","year":"2008","unstructured":"Sahasranaman, S., Howard, D. & Roy, S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol. 64(8), 753\u2013767. https:\/\/doi.org\/10.1007\/s00228-008-0478-6 (2008).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"24355_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00280-018-3525-8","volume":"81","author":"T Gerbek","year":"2018","unstructured":"Gerbek, T. et al. Role of TPMT and ITPA variants in mercaptopurine disposition. Cancer Chemother Pharmacol. 81(3), 579\u2013586. https:\/\/doi.org\/10.1007\/s00280-018-3525-8 (2018).","journal-title":"Cancer Chemother Pharmacol."},{"issue":"3","key":"24355_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.764","volume":"9","author":"L Ding","year":"2021","unstructured":"Ding, L. et al. Xanthine oxidase activity in thiopurine curative Chinese inflammatory bowel disease patients. Pharmacol. Res. Perspect. 9(3), e00764. https:\/\/doi.org\/10.1002\/prp2.764 (2021).","journal-title":"Pharmacol. Res. Perspect."},{"key":"24355_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cca.2019.08.024","volume":"499","author":"K Lampi\u010d","year":"2019","unstructured":"Lampi\u010d, K. et al. Determination of 6-thioguanine and 6-methylmercaptopurine in dried blood spots using liquid chromatography-tandem mass spectrometry: Method development, validation and clinical application. Clin. Chim. Acta. 499, 24\u201333. https:\/\/doi.org\/10.1016\/j.cca.2019.08.024 (2019).","journal-title":"Clin. Chim. Acta."},{"issue":"11","key":"24355_CR22","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/sj.leu.2402259","volume":"15","author":"T Dervieux","year":"2001","unstructured":"Dervieux, T. et al. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. Leukemia 15(11), 1706\u20131712. https:\/\/doi.org\/10.1038\/sj.leu.2402259 (2001).","journal-title":"Leukemia"},{"issue":"12","key":"24355_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","volume":"2","author":"LM Vrooman","year":"2018","unstructured":"Vrooman, L. M. et al. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05\u2013001. Blood Adv. 2(12), 1449\u20131458. https:\/\/doi.org\/10.1182\/bloodadvances.2018016584 (2018).","journal-title":"Blood Adv."},{"issue":"31","key":"24355_CR24","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/JCO.20.03692","volume":"39","author":"LM Vrooman","year":"2021","unstructured":"Vrooman, L. M. et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11\u2013001. J. Clin Oncol. 39(31), 3496\u20133505. https:\/\/doi.org\/10.1200\/JCO.20.03692 (2021).","journal-title":"J. Clin Oncol."},{"issue":"4","key":"24355_CR25","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/bloodadvances.2021005634","volume":"6","author":"TH Tran","year":"2022","unstructured":"Tran, T. H. et al. Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16\u2013001. Blood advs. 6(4), 1329\u20131341. https:\/\/doi.org\/10.1182\/bloodadvances.2021005634 (2022).","journal-title":"Blood advs."},{"issue":"2","key":"24355_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/clpt.2008.154","volume":"85","author":"G Stocco","year":"2009","unstructured":"Stocco, G. et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85(2), 164\u2013172. https:\/\/doi.org\/10.1038\/clpt.2008.154 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"24355_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/FPC.0000000000000533","volume":"34","author":"Z Sabirova","year":"2024","unstructured":"Sabirova, Z. et al. Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients. Pharmacogenet Genomics. 34(5), 170\u2013173. https:\/\/doi.org\/10.1097\/FPC.0000000000000533 (2024).","journal-title":"Pharmacogenet Genomics."},{"issue":"4","key":"24355_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2217\/pgs-2022-0164","volume":"24","author":"C Mootoosamy","year":"2023","unstructured":"Mootoosamy, C. et al. IL16 and factor V gene variations are associated with asparaginase-related thrombosis in childhood acute lymphoblastic leukemia patients. Pharmacogenomics 24(4), 199\u2013206. https:\/\/doi.org\/10.2217\/pgs-2022-0164 (2023).","journal-title":"Pharmacogenomics"},{"issue":"1","key":"24355_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas. Dermosifiliogr. 112(1), 90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009 (2021).","journal-title":"Actas. Dermosifiliogr."},{"issue":"6509","key":"24355_CR30","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"GTEx Consortium","year":"2020","unstructured":"GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369(6509), 1318\u20131330.  https:\/\/doi.org\/10.1126\/science.aaz1776 (2020).","journal-title":"Sci."},{"issue":"6","key":"24355_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/FTD.0b013e31815bf4dc","volume":"29","author":"DR Wong","year":"2007","unstructured":"Wong, D. R., Derijks, L. J., den Dulk, M. O., Gemmeke, E. H. & Hooymans, P. M. The role of xanthine oxidase in thiopurine metabolism: a case report. Ther. Drug Monit. 29(6), 845\u2013848. https:\/\/doi.org\/10.1097\/FTD.0b013e31815bf4dc (2007).","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"24355_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4212\/cjhp.v74i4.3199","volume":"74","author":"M Belhocine","year":"2021","unstructured":"Belhocine, M. et al. Optimizing thiopurine therapy with a xanthine oxidase inhibitor in patients with systemic autoimmune diseases: a single-centre experience. Can J Hosp Pharm. 74(4), 361\u2013369. https:\/\/doi.org\/10.4212\/cjhp.v74i4.3199 (2021).","journal-title":"Can J Hosp Pharm."},{"issue":"2","key":"24355_CR33","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/MPH.0000000000002313","volume":"44","author":"N Mosher","year":"2022","unstructured":"Mosher, N. et al. Utilization of thiopurine metabolites and allopurinol in pediatric acute lymphoblastic leukemia: consideration for an algorithmic approach. J. Pediatr. Hematol. Oncol. 44(2), e521\u2013e525. https:\/\/doi.org\/10.1097\/MPH.0000000000002313 (2022).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"24355_CR34","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3389\/fphar.2018.01107","volume":"9","author":"SZ Lim","year":"2018","unstructured":"Lim, S. Z. & Chua, E. W. Revisiting the role of thiopurines in inflammatory bowel disease through pharmacogenomics and use of novel methods for therapeutic drug monitoring. Front Pharmacol. 9, 1107. https:\/\/doi.org\/10.3389\/fphar.2018.01107 (2018).","journal-title":"Front Pharmacol."},{"key":"24355_CR35","doi-asserted-by":"publisher","first-page":"1159307","DOI":"10.3389\/fphar.2023.1159307","volume":"14","author":"AM Ali","year":"2023","unstructured":"Ali, A. M. et al. Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia. Front Pharmacol. 14, 1159307. https:\/\/doi.org\/10.3389\/fphar.2023.1159307 (2023).","journal-title":"Front Pharmacol."},{"issue":"12","key":"24355_CR36","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1097\/MIB.0000000000000570","volume":"21","author":"MN Lee","year":"2015","unstructured":"Lee, M. N. et al. Impact of genetic polymorphisms on 6-thioguanine nucleotide levels and toxicity in pediatric patients with IBD treated with azathioprine. Inflamm. Bowel Dis. 21(12), 2897\u20132908. https:\/\/doi.org\/10.1097\/MIB.0000000000000570 (2015).","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"24355_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1399-3046.2010.01367.x","volume":"14","author":"EL Ohmann","year":"2010","unstructured":"Ohmann, E. L. et al. Inosine 5\u2019-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients. Pediatr. Transplant. 14(7), 891\u2013895. https:\/\/doi.org\/10.1111\/j.1399-3046.2010.01367.x (2010).","journal-title":"Pediatr. Transplant."},{"issue":"9","key":"24355_CR38","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.bbmt.2018.04.006","volume":"24","author":"JS McCune","year":"2018","unstructured":"McCune, J. S. et al. Inosine monophosphate dehydrogenase pharmacogenetics in hematopoietic cell transplantation patients. Biol. Blood Marrow Transplant. 24(9), 1802\u20131807. https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.006 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"24355_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.bbmt.2011.06.014","volume":"18","author":"W Cao","year":"2012","unstructured":"Cao, W. et al. Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18(2), 273\u2013279. https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.014 (2012).","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"24355_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2125.2010.03867.X","volume":"71","author":"T Adam Beaumais","year":"2011","unstructured":"Adam Beaumais, T. et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br. J. Clin. Pharmacol. 71(4), 575\u2013584. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03867.X (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"24355_CR41","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/ph15040416","volume":"15","author":"Y Lee","year":"2022","unstructured":"Lee, Y., Jang, E. J., Yoon, H. Y., Yee, J. & Gwak, H. S. Effect of ITPA polymorphism on adverse drug reactions of 6-mercaptopurine in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Pharmaceuticals (Basel, Switzerland) 15(4), 416. https:\/\/doi.org\/10.3390\/ph15040416 (2022).","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"3","key":"24355_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00008571-200403000-00006","volume":"14","author":"AM Marinaki","year":"2004","unstructured":"Marinaki, A. M. et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14(3), 181\u2013187. https:\/\/doi.org\/10.1097\/00008571-200403000-00006 (2004).","journal-title":"Pharmacogenetics"},{"issue":"3","key":"24355_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1515\/jomb-2017-0060","volume":"37","author":"G Milosevic","year":"2018","unstructured":"Milosevic, G. et al. Variants in TPMT, ITPA, ABCC4 and ABCB1 genes as predictors of 6-mercaptopurine induced toxicity in children with acute lymphoblastic leukemia. J. Med. Biochem. 37(3), 320\u2013327. https:\/\/doi.org\/10.1515\/jomb-2017-0060 (2018).","journal-title":"J. Med. Biochem."},{"issue":"12","key":"24355_CR44","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","volume":"52","author":"W Stock","year":"2011","unstructured":"Stock, W. et al. Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk lymphoma. 52(12), 2237\u20132253. https:\/\/doi.org\/10.3109\/10428194.2011.596963 (2011).","journal-title":"Leuk lymphoma."},{"issue":"12","key":"24355_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.48803","volume":"5","author":"W Yang","year":"2022","unstructured":"Yang, W. et al. Association of inherited genetic factors with drug-induced hepatic damage among children with acute lymphoblastic leukemia. JAMA netw. open. 5(12), e2248803. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.48803 (2022).","journal-title":"JAMA netw. open."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24355-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24355-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24355-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T02:04:18Z","timestamp":1763863458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24355-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24355"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24355-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from every patient or parent\/legal guardian. The study was conducted in accordance with the Declaration of Helsinki and was approved by Research Ethics Board of SJUHC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}}],"article-number":"40519"}}